Hidradenitis

This study is testing whether Botox injections can reduce inflammation in people with hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps. Researchers believe that blocking certain nerve signals may calm the immune response. The study will enroll 20 …

This study offers continued treatment with povorcitinib for up to 600 adults with hidradenitis suppurativa who completed a prior trial and saw benefit. The main goal is to track side effects over time, with a secondary focus on reducing skin abscesses, nodules, and tunnels. Parti…

This study tests an oral drug called povorcitinib in 40 adolescents aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful boils and tunnels. Over 54 weeks, researchers will check the drug's safety, how the body processes it,…

This early-stage trial tests a cream called ruxolitinib on people with hidradenitis suppurativa, a condition causing painful lumps under the skin. The study includes 24 adults and teens and focuses on safety and how much of the drug gets into the body. Participants apply the crea…

This study tests whether NAV-240, given as an IV infusion, works better than a placebo for adults with moderate-to-severe hidradenitis suppurativa (HS). HS causes painful, inflamed bumps and tunnels under the skin. The main goal is to see if NAV-240 can reduce these bumps by at l…

This phase 3 study tests the long-term safety and effectiveness of remibrutinib, an oral drug, in 710 adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants have already completed a prior remibrutinib study. …

This study tests a drug called secukinumab in Chinese adults with moderate to severe hidradenitis suppurativa, a painful skin condition that causes boils and tunnels under the skin. The goal is to see if the drug reduces skin lesions and prevents flare-ups over 16 weeks. About 36…

This study tests a daily pill called ritlecitinib for adults with moderate to severe hidradenitis suppurativa (HS), a condition causing painful red skin lumps. About 240 participants who haven't been helped by antibiotics will be randomly assigned to get the drug or a placebo for…

This study tests an experimental drug called SAR445399 in 144 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition that causes abscesses and tunnels under the skin. Participants will receive one of two doses of the drug or a placebo for 32 weeks.…

This study follows 142 Canadian adults with moderate-to-severe hidradenitis suppurativa who are prescribed secukinumab as part of their regular care. Researchers will track changes in disease severity over 12 months using a standard scoring system. The goal is to understand how w…

This Phase 2 study tests brivekimig, an injected drug, in 208 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses and tunnels. Participants receive different doses of brivekimig or a placebo for up to 48 weeks. The main…

This first-in-human trial tests an oral drug called SAR447971 (KT-485) in healthy volunteers and people with hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. The study has three parts: single and multiple doses in healthy people, and multiple doses i…

This early-phase trial tests siplizumab, a drug given as a shot under the skin, in 12 adults with moderate-to-severe hidradenitis suppurativa (painful boils) that hasn't improved with standard treatments. The main goal is to see if the drug safely reduces the number of inflamed l…

This study tests a new drug called BFB759 for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition that causes boils and abscesses. About 210 adults will receive either BFB759 or a placebo to see if the drug reduces the number of painful bumps an…

This study tests whether high-dose radiotherapy can improve symptoms of hidradenitis suppurativa, a painful skin condition. Ten adults with moderate to severe disease will receive radiation to one armpit while the other armpit gets standard care. Researchers will compare changes …

This study tests a new injectable drug called LAD191 in 200 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition causing abscesses and scarring. Participants will receive either LAD191, a placebo, or an active comparator (adalimumab) to see if LA…

This study tests an experimental drug called SCT650C in 60 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing boils and tunnels. The goal is to see if the drug can reduce abscesses and inflammation by at least 75% after 16 weeks. Partic…

This study tracks the safety and effectiveness of the drug Cosentyx (secukinumab) in Korean patients with hidradenitis suppurativa, pediatric plaque psoriasis, or juvenile idiopathic arthritis. Researchers will monitor 76 participants for side effects and how well the drug works …

This study tests a new drug called zasocitinib for people with moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful, pus-filled bumps. About 90 adults will receive either the drug or a placebo for 4 months, then all will get the drug for 8 more month…

This early study tests whether taking capsules containing donor fecal bacteria can change the gut and skin bacteria of people with hidradenitis suppurativa (HS), a painful skin condition. Sixteen adults with HS will receive either the bacteria capsules or a placebo for three week…

This early-stage trial is testing a new drug called HB0043 in 15 adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. The drug is a bispecific antibody that targets two inflammatory proteins (IL-17A and IL-36R) to reduc…

This study tests a medicated foam (roflumilast) applied to the skin for hidradenitis suppurativa, a painful inflammatory condition. Ten adults will use the foam alone or with their usual treatments for 4 months. Researchers will check if it improves symptoms and analyze skin gene…

This program provides access to secukinumab (AIN457) for people with hidradenitis suppurativa who have no other treatment options. It is for patients with serious disease who cannot join a clinical trial or have exhausted all available therapies. Doctors must request access on be…

This study tests whether the experimental drug LAD328 can reduce symptoms of hidradenitis suppurativa, a chronic skin condition causing painful lumps. About 50 adults with moderate-to-severe disease will receive either LAD328 or a placebo. The main goal is to see if the drug lead…

This study tests a medicated foam (roflumilast) applied to the skin for hidradenitis suppurativa, a condition causing painful bumps and abscesses. About 20 adults with mild to moderate HS will use the foam for 16 weeks. The goal is to see if it reduces the number of inflamed nodu…

This study compares a new wound dressing, Pelashield PainGuard, to the standard Restrata dressing for people with severe hidradenitis suppurativa (HS) who need surgery. The new dressing contains silver to fight bacteria and lidocaine to numb pain. Researchers will track healing t…

This study tests whether a new drug called CIT-013 can reduce symptoms of hidradenitis suppurativa, a chronic skin condition causing painful lumps. About 96 adults with moderate to severe HS will receive either 50 mg, 100 mg, or a placebo every two weeks for 12 weeks. Researchers…

This study surveys 77 adults with moderate to severe hidradenitis suppurativa (HS) in Saudi Arabia who are starting the medication Cosentyx (secukinumab). Researchers will ask patients about their treatment satisfaction and quality of life after 24 weeks. The goal is to understan…

This pilot study tests a 1726-nm laser (AviClear) to reduce painful lumps and abscesses in hidradenitis suppurativa (HS), a chronic skin condition. Thirty adults with mild-to-moderate HS will have one side of their body treated with the laser and the other side with a sham proced…

This observational study uses brain imaging to explore whether people with hidradenitis suppurativa (HS) have differences in resting brain activity compared to healthy individuals. Researchers will also track how these brain patterns relate to disease severity, pain, sleep, mood,…

This study investigates how inflammatory genes are regulated in people with hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. Researchers will compare inflammatory markers in HS patients versus healthy controls. An optional sub-study explores whether …

This observational study aims to collect and analyze data from up to two million patients with dermatologic conditions like vitiligo, atopic dermatitis, alopecia areata, and hidradenitis suppurativa, as well as their healthcare providers. By reviewing treatment patterns, outcomes…

This study follows 250 Italian adults with moderate to severe hidradenitis suppurativa (a chronic skin disease causing painful lumps) who are starting secukinumab. Researchers will track how well the drug reduces skin lesions over time and how it affects healthcare use and costs.…

This study looks at how much of the drug bimekizumab passes into breast milk. Researchers will collect milk samples from 20 breastfeeding mothers with conditions like psoriasis or arthritis over several weeks. The goal is to understand potential exposure for nursing infants, not …

This observational study follows 800 adults who receive Myriad™ during soft tissue reconstruction for wounds like abdominal dehiscence, pressure injuries, or anal fistulas. Researchers track healing time, complications, and side effects to understand how well the material works i…

This international study observes how people with hidradenitis suppurativa (a chronic skin condition) access healthcare, what treatments they receive, and how the disease affects their quality of life. Researchers collect data from routine medical records across multiple countrie…

This study is collecting skin and blood samples from 830 people with chronic inflammatory skin diseases like psoriasis, eczema, and lupus. Researchers want to find biological markers that can predict how well a person will respond to treatment after one year. The goal is to move …

This study is collecting data from 1,000 people with hidradenitis suppurativa (HS), a painful and poorly understood skin condition. Researchers aim to identify key clinical and biological features of HS to create a classification system and find potential treatment targets. Parti…

This study is creating a large registry of 3,000 people with hidradenitis suppurativa (HS), a painful and poorly understood skin condition. Researchers will collect medical information and biological samples over time to learn more about how HS progresses and what causes it. The …

This study monitors 36 people who previously received an experimental gene-modified regulatory T cell (Treg) therapy for rheumatoid arthritis or hidradenitis suppurativa. The goal is to check for any delayed side effects and see how long the modified cells last in the body. Parti…

This study collects skin samples from 500 people with conditions like acne, eczema, and psoriasis, as well as healthy volunteers. Researchers will analyze the samples to find biomarkers and gene patterns linked to inflammation. The goal is to better understand these skin diseases…

This study collects skin samples and medical information from people with hidradenitis suppurativa and other skin conditions. The goal is to create a biobank that scientists can use in future studies to better understand inflammatory skin disorders. Participants are seen at Ohio …

This study aims to understand how alopecia areata, vitiligo, and hidradenitis suppurativa affect the quality of life and daily functioning of teenagers and adults. Researchers will collect information from nearly 2,800 participants across multiple countries using surveys and skin…

This study is following 465 people with hidrosadenitis (a painful skin condition) to identify different forms of the disease. Researchers hope that by understanding these variations, they can develop better, more personalized treatments. No new drugs or procedures are being teste…